A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

por Jonsson, F, Ou, Y, Claret, L, Siegel, D, Jagannath, S, Vij, R, Badros, A, Aggarwal, S, Bruno, R
Publicado 2015

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

por Badros, A Z, Vij, R, Martin, T, Zonder, J A, Kunkel, L, Wang, Z, Lee, S, Wong, A F, Niesvizky, R
Publicado 2013

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study

por Greenberg, A J, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, R A, Kumar, S, Vachon, C M, Rajkumar, S V
Publicado 2015

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study

por Greenberg, A J, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, R A, Kumar, S, Vachon, C M, Rajkumar, S V
Publicado 2015

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por van de Donk, N. W. C. J, Popat, R, Hulin, C, Jagannath, S, Oriol, A, Richardson, P. G, Facon, T, Weisel, K, Larsen, J. T, Minnema, M, Abdallah, A, Badros, A. Z, Knop, S, Stadtmauer, E. A, Chen, M, Nguyen, T. V, Amin, A, Peluso, T, Lonial, S
Publicado 2022

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

por Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.
Publicado 2023

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

por Rapoport, AP, Meisenberg, B, Sarkodee-Adoo, C, Fassas, A, Frankel, SR, Mookerjee, B, Takebe, N, Fenton, R, Heyman, M, Badros, A, Kennedy, A, Jacobs, M, Hudes, R, Ruehle, K, Smith, R, Kight, L, Chambers, S, MacFadden, M, Cottler-Fox, M, Chen, T, Phillips, G, Tricot, G
Publicado 2002

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

por Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Publicado 2022